- •Presentation and recurrence of acquired TTR amyloidosis resembles donor's phenotype.
- •Liver re-transplantation for acquired TTR amyloidosis does not halt amyloid deposit.
- •Amyloid deposits after liver re-transplantation are composed of wtTTR.
Reports of acquired ATTRm in domino liver transplant (DLT) recipients are infrequent and the approach to management is unknown. We describe two patients, an inherited ATTRm patient who underwent liver transplant and his liver recipient who developed acquired ATTRm 8 years following transplantation. The clinical manifestations of amyloidosis were similar between patients and consisted of peripheral neuropathy, diarrhea and weight loss. Following liver transplantation, the DLT donor went into remission for 4 years, but eventually progressed and died. The DLT recipient was re-transplanted with a healthy liver, but amyloidosis progressed after 5 years, with symptoms resembling the progression of the ATTRm liver donor. Proteomic analysis was utilized to type the amyloid deposits present in the DLT recipient fat aspirate specimen obtained prior to the second transplantation and stomach biopsy obtained at disease progression. The fat amyloid deposits contained almost equal amounts of mutant TTR and wild-type TTR peptides, but the stomach biopsy showed only wild-type TTR. There is a high concordance of disease phenotype between inherited and acquired ATTRm, which may help in early recognition of acquired ATTRm in DLT recipients. Liver re-transplantation for acquired ATTRm may not interrupt the cycle of amyloid deposition since normal hepatically produced TTR may co-deposit with trace amount of pre-existing TTRm amyloid.
Abbreviations:ATTRm (mutated transthyretin amyloidosis), DLT (Domino liver transplant), EF (ejection fraction), GI (Gastrointestinal), IVS (Interventricular septum), LV (left ventricle), MS/MS (tandem mass spectrometry), OLT (Orthotopic liver transplantation), TTR (Transthyretin), TTRm (mutated transthyretin), TTRwt (wild-type transthyretin), TUDCA (Tauroursodeoxycholic acid)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.J. Biol. Chem. 2001; 276: 27207-27213
- Familial amyloid polyneuropathy.Lancet Neurol. 2011; 10: 1086-1097
- Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.Lancet. 1993; 341: 1113-1116
- Progression of ventricular wall thickening after liver transplantation for familial amyloidosis.Transplantation. 1997; 64: 74-80
- Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients.Amyloid. 2011; 18: 200-205
- Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type.Transplantation. 2002; 73: 745-751
- Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy.Transplantation. 1998; 65: 918-925
- Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis.Transplantation. 1998; 66: 229-233
- Liver transplantation in transthyretin amyloidosis: issues and challenges.Liver Transpl. 2015; 21: 282-292
- Single-centre experience of liver transplantation for familial amyloidotic polyneuropathy of non-Val30Met variants in Chinese patients.Amyloid. 2012; 19: 33-36
- Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation.Amyloid. 2007; 14: 277-282
- Progression of transthyretin amyloid neuropathy after liver transplantation.Neurology. 2010; 75: 324-327
- Pathophysiology and treatment of cardiac amyloidosis.Nat. Rev. Cardiol. 2015; 12: 91-102
- Accessed January 12, 2017)
- Systemic but asymptomatic transthyretin amyloidosis 8 years after domino liver transplantation.J. Neurol. Neurosurg. Psychiatry. 2011; 82: 1287-1290
- Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation.Liver Transpl. 2010; 16: 1386-1392
- Recipient aging accelerates acquired transthyretin amyloidosis after domino liver transplantation.Liver Transpl. 2016; 22: 656-664
- Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers.Lab. Investig. 2004; 84: 865-873
- Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver.Liver Transpl. 2007; 13: 215-218
- The pathological and biochemical identification of possible seed-lesions of transmitted transthyretin amyloidosis after domino liver transplantation. The journal of pathology.Clin. Res. 2016; 2: 72-79
- Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.Circulation. 2016; 133: 2404-2412
- Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.Blood. 2009; 114: 4957-4959
- Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.Haematologica. 2014; 99: 1239-1247
- Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis.J. Mass Spectrom. 2013; 48: 1067-1077
- Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses.J. Proteome Res. 2014; 13: 2352-2358
- Diagnosis, prognosis, and therapy of transthyretin amyloidosis.J. Am. Coll. Cardiol. 2015; 66: 2451-2466
- Amyloid deposition in ocular tissues of patients with familial amyloidotic polyneuropathy (FAP).Amyloid. 2002; 9: 183-189
- Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates.Am. J. Pathol. 2001; 159: 1993-2000
- Age and gender specific pediatric reference intervals for aldolase, amylase, ceruloplasmin, creatine kinase, pancreatic amylase, prealbumin, and uric acid.Clin. Chim. Acta. 2011; 412: 788-790
- An aggressive form of familial amyloid polyneuropathy caused by a Glu54Gly mutation in the transthyretin gene.Eur. J. Neurol. 2005; 12: 657-659
- Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation.Am. J. Transplant. 2006; 6: 2512-2515
- Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation.N. Engl. J. Med. 2005; 352: 2356
- Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation.Liver Transpl. 2010; 16: 109
- Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form.Arch. Neurol. 2002; 59: 1771-1776
Published online: June 13, 2017
Accepted: June 12, 2017
Received in revised form: June 8, 2017
Received: April 6, 2017
© 2017 Elsevier B.V. All rights reserved.